Literature DB >> 3969311

Chronic granulomatous disease: uptake and intracellular activity of fosfomycin in granulocytes.

P H Höger, R A Seger, U B Schaad, W H Hitzig.   

Abstract

In chronic granulomatous disease (CGD) polymorphonuclear leukocytes (PMN) are unable to kill phagocytized catalase-positive bacteria. Therefore, patients with CGD are prone to infections and dependent on antimicrobial agents able to penetrate PMN membranes and to act intracellularly. Owing to their good lipid solubility, trimethoprim/sulfamethoxazole and rifampicin passively diffuse the membrane. In contrast, fosfomycin is transported actively into the cell. In normal PMN, it reaches cellular-to-extracellular ratios of 1.83 after 15 min, in CGD-PMN 2.18 after 30 min. At concentrations between 16 and 200 mg/liter, fosfomycin was able to kill staphylococci surviving within CGD-PMN, thus compensating for the bactericidal deficiency in CGD. A combination of low concentrations of fosfomycin (8 mg/liter) plus rifampicin (0.06 mg/liter) was more effective at the intracellular level than either agent alone. Apart from a stimulation of PMN-chemiluminescence of yet unknown significance, the agent did not interfere with other neutrophil functions. Clinical investigations are indicated to study whether fosfomycin can be added to the small number of antibiotics useful in CGD.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3969311     DOI: 10.1203/00006450-198501000-00011

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

Review 1.  Plasmid-encoded fosfomycin resistance.

Authors:  J E Suárez; M C Mendoza
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Penetration of brodimoprim into human neutrophils and intracellular activity.

Authors:  P C Braga; M Dal Sasso; S Maci; G Bondiolotti; E Fonti; S Reggio
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Uptake, intracellular activity, and influence of rifampin on normal function of polymorphonuclear leukocytes.

Authors:  P H Höger; K Vosbeck; R Seger; W H Hitzig
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

4.  The management of chronic granulomatous disease.

Authors:  A Fischer; A W Segal; R Seger; R S Weening
Journal:  Eur J Pediatr       Date:  1993-11       Impact factor: 3.183

5.  Fosfomycin for the initial treatment of acute haematogenous osteomyelitis.

Authors:  N Corti; F H Sennhauser; U G Stauffer; D Nadal
Journal:  Arch Dis Child       Date:  2003-06       Impact factor: 3.791

6.  Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus.

Authors:  R Haag
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

Review 7.  Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review.

Authors:  Suzanne Bongers; Pien Hellebrekers; Luke P H Leenen; Leo Koenderman; Falco Hietbrink
Journal:  Antibiotics (Basel)       Date:  2019-05-04

Review 8.  In vitro antibiotic activity against intraosteoblastic Staphylococcus aureus: a narrative review of the literature.

Authors:  Florian C Marro; Lélia Abad; Ariel J Blocker; Frédéric Laurent; Jérôme Josse; Florent Valour
Journal:  J Antimicrob Chemother       Date:  2021-11-12       Impact factor: 5.790

9.  Penetration of fosfomycin into IPEC-J2 cells in the presence or absence of deoxynivalenol.

Authors:  Guadalupe Martínez; Denisa S Pérez; Alejandro L Soraci; María O Tapia
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.